CN101375990A - Composition for treating cardiovascular disease and preparation thereof - Google Patents
Composition for treating cardiovascular disease and preparation thereof Download PDFInfo
- Publication number
- CN101375990A CN101375990A CNA2007101210280A CN200710121028A CN101375990A CN 101375990 A CN101375990 A CN 101375990A CN A2007101210280 A CNA2007101210280 A CN A2007101210280A CN 200710121028 A CN200710121028 A CN 200710121028A CN 101375990 A CN101375990 A CN 101375990A
- Authority
- CN
- China
- Prior art keywords
- ophiopogonone
- ophiopogonin
- extract
- weight portion
- add
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 45
- 239000000203 mixture Substances 0.000 title claims abstract description 32
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 15
- 229930182490 saponin Natural products 0.000 claims abstract description 104
- 150000007949 saponins Chemical class 0.000 claims abstract description 104
- 235000017709 saponins Nutrition 0.000 claims abstract description 104
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims abstract description 90
- 239000000284 extract Substances 0.000 claims abstract description 79
- 235000002789 Panax ginseng Nutrition 0.000 claims abstract description 69
- 235000008434 ginseng Nutrition 0.000 claims abstract description 25
- 241000208340 Araliaceae Species 0.000 claims abstract description 24
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 24
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 24
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims abstract description 21
- FHKHGNFKBPFJCB-UHFFFAOYSA-N (25S)-ruscogenin 1-O-<alpha-L-rhamnopyranosyl(1->2)><beta-D-xylopyranosyl(1->3)>-beta-D-fucopyranoside Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C45C)C)C1CC2C3CC=C4CC(O)CC5OC(C1OC2C(C(O)C(O)C(C)O2)O)OC(C)C(O)C1OC1OCC(O)C(O)C1O FHKHGNFKBPFJCB-UHFFFAOYSA-N 0.000 claims abstract description 19
- FHKHGNFKBPFJCB-LYLKFOBISA-N Ophiopogonin D Chemical compound O([C@H]1[C@@H](O)[C@@H](C)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@@H]1C[C@H](O)CC2=CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@]21C)C)[C@@H]([C@]1(OC[C@H](C)CC1)O5)C)[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O FHKHGNFKBPFJCB-LYLKFOBISA-N 0.000 claims abstract description 19
- 229930003944 flavone Natural products 0.000 claims abstract description 19
- 235000011949 flavones Nutrition 0.000 claims abstract description 19
- IDGCVTONMQMXPU-JHZREZMDSA-N ophiopogonin D Natural products C[C@@H]1CC[C@@]2(OC1)O[C@H]3C[C@H]4[C@@H]5CC=C6C[C@@H](O)C[C@@H](O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O)[C@H]7O[C@@H]9O[C@@H](C)[C@H](O)[C@@H](O)[C@H]9O)[C@]6(C)[C@H]5CC[C@]4(C)[C@H]3[C@@H]2C IDGCVTONMQMXPU-JHZREZMDSA-N 0.000 claims abstract description 19
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims abstract description 18
- 150000002212 flavone derivatives Chemical class 0.000 claims abstract description 18
- DQYACEDUQHWXQZ-UHFFFAOYSA-N (25R)-spirost-5-en-3beta-ol 3-O-<O-alpha-L-rhamnopyranosyl-(1-2)-O-<alpha-L-arabinopyranosyl-(1-3)>-beta-D-glucopyranoside> Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC(C1OC2C(C(O)C(O)C(C)O2)O)OC(CO)C(O)C1OC1OCC(O)C(O)C1O DQYACEDUQHWXQZ-UHFFFAOYSA-N 0.000 claims abstract description 15
- NJYZGIOABZGGBB-UHFFFAOYSA-N Ophiopogonin D' Natural products CC1CCC2(OC1)OC3CC4C5CC=C6CC(CCC6(C)C5CCC4(C)C3C2C)OC7OC(CO)C(O)C(OC8OCC(O)C(O)C8OC9OC(C)C(O)C(O)C9O)C7O NJYZGIOABZGGBB-UHFFFAOYSA-N 0.000 claims abstract description 15
- BXTNNJIQILYHJB-GFCCVEGCSA-N Methylophiopogonanone A Natural products C1=C2OCOC2=CC(C[C@@H]2COC3=C(C)C(O)=C(C(=C3C2=O)O)C)=C1 BXTNNJIQILYHJB-GFCCVEGCSA-N 0.000 claims abstract description 14
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 claims abstract description 13
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 claims abstract description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 152
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 103
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 89
- 239000000243 solution Substances 0.000 claims description 85
- 229930190714 ophiopogonone Natural products 0.000 claims description 80
- 229930190017 ophiopogonin Natural products 0.000 claims description 70
- 238000000605 extraction Methods 0.000 claims description 51
- 239000007788 liquid Substances 0.000 claims description 51
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 36
- 238000010828 elution Methods 0.000 claims description 36
- 239000003814 drug Substances 0.000 claims description 33
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 31
- 239000000047 product Substances 0.000 claims description 30
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 claims description 29
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 29
- 239000003208 petroleum Substances 0.000 claims description 29
- 238000002347 injection Methods 0.000 claims description 25
- 239000007924 injection Substances 0.000 claims description 25
- 229940079593 drug Drugs 0.000 claims description 23
- 239000008215 water for injection Substances 0.000 claims description 23
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 22
- 238000003756 stirring Methods 0.000 claims description 22
- 229930182494 ginsenoside Natural products 0.000 claims description 21
- 229940089161 ginsenoside Drugs 0.000 claims description 21
- 239000012528 membrane Substances 0.000 claims description 20
- 239000002904 solvent Substances 0.000 claims description 19
- 238000001035 drying Methods 0.000 claims description 18
- 238000010521 absorption reaction Methods 0.000 claims description 17
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 16
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 15
- 229930195725 Mannitol Natural products 0.000 claims description 15
- 239000000594 mannitol Substances 0.000 claims description 15
- 235000010355 mannitol Nutrition 0.000 claims description 15
- 239000011347 resin Substances 0.000 claims description 14
- 229920005989 resin Polymers 0.000 claims description 14
- 239000000523 sample Substances 0.000 claims description 14
- -1 methyl Methylophiopogonanone A Chemical compound 0.000 claims description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- 238000001179 sorption measurement Methods 0.000 claims description 12
- 238000001556 precipitation Methods 0.000 claims description 11
- 238000005406 washing Methods 0.000 claims description 11
- 238000005325 percolation Methods 0.000 claims description 10
- 238000004321 preservation Methods 0.000 claims description 10
- 238000004440 column chromatography Methods 0.000 claims description 9
- 239000012535 impurity Substances 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 230000000274 adsorptive effect Effects 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 239000003480 eluent Substances 0.000 claims description 8
- 230000007935 neutral effect Effects 0.000 claims description 8
- 239000012043 crude product Substances 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 238000010992 reflux Methods 0.000 claims description 7
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 6
- 239000012567 medical material Substances 0.000 claims description 5
- 230000001376 precipitating effect Effects 0.000 claims description 5
- 238000007670 refining Methods 0.000 claims description 5
- 239000000470 constituent Substances 0.000 claims description 4
- 230000006837 decompression Effects 0.000 claims description 4
- 238000011084 recovery Methods 0.000 claims description 4
- 239000000741 silica gel Substances 0.000 claims description 4
- 229910002027 silica gel Inorganic materials 0.000 claims description 4
- 238000010898 silica gel chromatography Methods 0.000 claims description 4
- 238000012546 transfer Methods 0.000 claims description 4
- 238000001291 vacuum drying Methods 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 20
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 abstract description 8
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 abstract description 6
- 208000031225 myocardial ischemia Diseases 0.000 abstract description 6
- 230000000703 anti-shock Effects 0.000 abstract description 4
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 abstract description 2
- 241001465754 Metazoa Species 0.000 abstract description 2
- 244000248557 Ophiopogon japonicus Species 0.000 abstract 5
- UFMAZRUMVFVHLY-CYBMUJFWSA-N Methylophiopogonanone B Natural products C1=CC(OC)=CC=C1C[C@H]1C(=O)C2=C(O)C(C)=C(O)C(C)=C2OC1 UFMAZRUMVFVHLY-CYBMUJFWSA-N 0.000 abstract 1
- 240000004371 Panax ginseng Species 0.000 abstract 1
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 abstract 1
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 abstract 1
- AUTZLTCWRDPAPV-UHFFFAOYSA-N methylophiopogonone A Chemical compound C1=C2OCOC2=CC(CC2=COC3=C(C)C(O)=C(C(=C3C2=O)O)C)=C1 AUTZLTCWRDPAPV-UHFFFAOYSA-N 0.000 abstract 1
- BUTFXZVBLOLETI-UHFFFAOYSA-N methylophiopogonone B Chemical compound C1=CC(OC)=CC=C1CC1=COC2=C(C)C(O)=C(C)C(O)=C2C1=O BUTFXZVBLOLETI-UHFFFAOYSA-N 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 57
- 239000013558 reference substance Substances 0.000 description 27
- 238000012360 testing method Methods 0.000 description 27
- 229940090044 injection Drugs 0.000 description 22
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 238000005303 weighing Methods 0.000 description 14
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 9
- 239000000945 filler Substances 0.000 description 9
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 9
- 239000000377 silicon dioxide Substances 0.000 description 9
- 238000011003 system suitability test Methods 0.000 description 9
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 238000003908 quality control method Methods 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 238000000105 evaporative light scattering detection Methods 0.000 description 7
- 239000007789 gas Substances 0.000 description 7
- 238000004811 liquid chromatography Methods 0.000 description 7
- 230000000747 cardiac effect Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 230000002107 myocardial effect Effects 0.000 description 6
- 230000033228 biological regulation Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 210000004165 myocardium Anatomy 0.000 description 5
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 5
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 3
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 206010007625 cardiogenic shock Diseases 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229960002275 pentobarbital sodium Drugs 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000012088 reference solution Substances 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- XXDBCABHQMLKHQ-UHFFFAOYSA-N 2-methyl-2-phenyl-3h-chromen-4-one Chemical compound C1C(=O)C2=CC=CC=C2OC1(C)C1=CC=CC=C1 XXDBCABHQMLKHQ-UHFFFAOYSA-N 0.000 description 2
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 2
- 206010002660 Anoxia Diseases 0.000 description 2
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 2
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000003177 cardiotonic effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 description 2
- 238000010812 external standard method Methods 0.000 description 2
- 239000008862 fructus schizandrae, radix ginseng, radix ophiopogonis drug combination Substances 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 208000037906 ischaemic injury Diseases 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 239000010413 mother solution Substances 0.000 description 2
- 229940100243 oleanolic acid Drugs 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- SHCBCKBYTHZQGZ-DLHMIPLTSA-N protopanaxatriol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2[C@@H](O)C[C@@]3(C)[C@]4(C)CC[C@H]([C@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C SHCBCKBYTHZQGZ-DLHMIPLTSA-N 0.000 description 2
- BBEUDPAEKGPXDG-UHFFFAOYSA-N protopanaxatriol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC3C4(C)CCC(O)C(C)(C)C4C(O)CC23C BBEUDPAEKGPXDG-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- NFZYDZXHKFHPGA-UHFFFAOYSA-N 17alpha-hydroxygofruside Natural products C12CC(C)(C)CCC2(C(=O)OC2C(C(O)C(O)C(CO)O2)O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OC(C(O)=O)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O NFZYDZXHKFHPGA-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- QXQFFGOMXYKNBA-UHFFFAOYSA-N Chikusetsusaponin V Natural products CC1(C)CCC2(CCC3C(=CCC4C3(C)CCC5C(C)(C)C(CCC45C)OC6OC(C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C(=O)O)C2C1)C(=O)OC8OC(CO)C(O)C(O)C8O QXQFFGOMXYKNBA-UHFFFAOYSA-N 0.000 description 1
- NFZYDZXHKFHPGA-QQHDHSITSA-N Chikusetsusaponin-V Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CCC(C[C@H]14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NFZYDZXHKFHPGA-QQHDHSITSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- KSIVGTKSVYIZEB-GDUJLLAZSA-N Ophiopogonin A Chemical compound O([C@@H]1[C@@H](O)[C@@H](O)[C@@H](C)O[C@H]1O[C@@H]1C[C@H](O)CC2=CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@]21C)C)[C@@H]([C@]1(OC[C@H](C)CC1)O5)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](OC(C)=O)[C@H]1O KSIVGTKSVYIZEB-GDUJLLAZSA-N 0.000 description 1
- KAKIFWVVJIJRCX-UHFFFAOYSA-N Ophiopogonin B' Natural products CC1CCC2(OC1)OC3CC4C5CC=C6CC(CCC6(C)C5CCC4(C)C3C2C)OC7OC(CO)C(O)C(OC8OCC(O)C(O)C8O)C7OC9OC(C)C(OC(=O)C)C(O)C9O KAKIFWVVJIJRCX-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- VIXIMKLMEZTTTC-UHFFFAOYSA-N Panaxatriol Natural products CC1(C)CCCC(O1)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5C(O)CC34C VIXIMKLMEZTTTC-UHFFFAOYSA-N 0.000 description 1
- QFJUYMMIBFBOJY-UXZRXANASA-N Panaxatriol Chemical compound C[C@]1([C@H]2CC[C@@]3([C@@H]2[C@H](O)C[C@H]2[C@]3(C[C@@H](O)[C@H]3C(C)(C)[C@@H](O)CC[C@@]32C)C)C)CCCC(C)(C)O1 QFJUYMMIBFBOJY-UXZRXANASA-N 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DWCSNWXARWMZTG-UHFFFAOYSA-N Trigonegenin A Natural products CC1C(C2(CCC3C4(C)CCC(O)C=C4CCC3C2C2)C)C2OC11CCC(C)CO1 DWCSNWXARWMZTG-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- WQLVFSAGQJTQCK-VKROHFNGSA-N diosgenin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 WQLVFSAGQJTQCK-VKROHFNGSA-N 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- NODILNFGTFIURN-GZPRDHCNSA-N ginsenoside Rb2 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O NODILNFGTFIURN-GZPRDHCNSA-N 0.000 description 1
- PFSIGTQOILYIIU-UHFFFAOYSA-N ginsenoside Rb3 Natural products CC(=CCCC(C)(O)C1CCC2(C)C3CCC4C(C)(C)C(CCC4(C)C3CC(OC5OC(COC6OCC(O)C(O)C6O)C(O)C(O)C5O)C12C)OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C PFSIGTQOILYIIU-UHFFFAOYSA-N 0.000 description 1
- RBRANZURTULKJD-UHFFFAOYSA-N ginsenoside Ro Natural products CC1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(OC6OC(C)(C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C(=O)O)C(C)(C)C5CCC34C)C2C1)C(=O)OC8OC(CO)C(O)C(O)C8O RBRANZURTULKJD-UHFFFAOYSA-N 0.000 description 1
- ZTQSADJAYQOCDD-UHFFFAOYSA-N ginsenoside-Rd2 Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OCC(O)C(O)C1O ZTQSADJAYQOCDD-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940093181 glucose injection Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- KSIVGTKSVYIZEB-UHFFFAOYSA-N lirioplioside B Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C45C)C)C1CC2C3CC=C4CC(O)CC5OC1OC(C)C(O)C(O)C1OC1OC(C)C(O)C(OC(C)=O)C1O KSIVGTKSVYIZEB-UHFFFAOYSA-N 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 230000002879 macerating effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 239000002664 nootropic agent Substances 0.000 description 1
- 230000001777 nootropic effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- NWMIYTWHUDFRPL-UHFFFAOYSA-N sapogenin Natural products COC(=O)C1(CO)C(O)CCC2(C)C1CCC3(C)C2CC=C4C5C(C)(O)C(C)CCC5(CCC34C)C(=O)O NWMIYTWHUDFRPL-UHFFFAOYSA-N 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 229930002600 steroidal saponin Natural products 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Description
Claims (11)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007101210280A CN101375990B (en) | 2007-08-29 | 2007-08-29 | Composition for treating cardiovascular disease and preparation thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007101210280A CN101375990B (en) | 2007-08-29 | 2007-08-29 | Composition for treating cardiovascular disease and preparation thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101375990A true CN101375990A (en) | 2009-03-04 |
CN101375990B CN101375990B (en) | 2012-05-02 |
Family
ID=40419836
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007101210280A Expired - Fee Related CN101375990B (en) | 2007-08-29 | 2007-08-29 | Composition for treating cardiovascular disease and preparation thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101375990B (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101879274A (en) * | 2010-07-12 | 2010-11-10 | 徐俊 | Medicine composition containing red ginseng saponin extract and radix ophiopogonis saponin extract as well as preparation method and application thereof |
CN102133333A (en) * | 2011-03-25 | 2011-07-27 | 浙江大学 | Quality control method for shenmai injection mass spectrum finger prints |
CN102988399A (en) * | 2012-12-21 | 2013-03-27 | 周志欢 | Medicine composition and application and preparation thereof |
CN103393708A (en) * | 2013-08-20 | 2013-11-20 | 大理药业股份有限公司 | Ginsenoside-ophiopogonin D composition for treating cardiovascular and cerebrovascular diseases |
CN104623262A (en) * | 2013-11-12 | 2015-05-20 | 雅安三九药业有限公司 | Red ginseng and dwarf lilyturf tuber injection as well as preparation method thereof |
CN105004830A (en) * | 2015-07-21 | 2015-10-28 | 成都中医药大学 | HPLC-ELSD method for simultaneously determining five saponin components in ophiopogon japonicus |
CN107823420A (en) * | 2017-11-09 | 2018-03-23 | 华润三九(雅安)药业有限公司 | The preparation method and Shenmai injection of Shenmai injection |
CN109709250A (en) * | 2018-12-28 | 2019-05-03 | 南京海昌中药集团有限公司 | The detection method of ginseng antler medical liquor finger-print |
CN112294794A (en) * | 2019-08-01 | 2021-02-02 | 四川大学 | Application of methyl ophiopogonone A in preparation of medicine for preventing and/or treating non-alcoholic fatty liver disease and liver injury |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100484557C (en) * | 2005-09-08 | 2009-05-06 | 刘玉辉 | Chinese medicine compound preparation for treating myocardial ischemia and improving microcirculation, and preparing method thereof |
CN1943710A (en) * | 2005-10-03 | 2007-04-11 | 徐东铭 | The application of radix ophioponis in the medicines for treating myocarditis and medicines containing its extracts with active elements |
-
2007
- 2007-08-29 CN CN2007101210280A patent/CN101375990B/en not_active Expired - Fee Related
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101879274B (en) * | 2010-07-12 | 2012-10-17 | 哈尔滨吉尔生物科技有限公司 | Medicine composition containing red ginseng saponin extract and radix ophiopogonis saponin extract as well as preparation method and application thereof |
CN101879274A (en) * | 2010-07-12 | 2010-11-10 | 徐俊 | Medicine composition containing red ginseng saponin extract and radix ophiopogonis saponin extract as well as preparation method and application thereof |
CN102133333A (en) * | 2011-03-25 | 2011-07-27 | 浙江大学 | Quality control method for shenmai injection mass spectrum finger prints |
CN102133333B (en) * | 2011-03-25 | 2013-06-12 | 浙江大学 | Quality control method for shenmai injection mass spectrum finger prints |
CN102988399A (en) * | 2012-12-21 | 2013-03-27 | 周志欢 | Medicine composition and application and preparation thereof |
CN103393708B (en) * | 2013-08-20 | 2015-06-03 | 大理药业股份有限公司 | Ginsenoside-ophiopogonin D composition for treating cardiovascular and cerebrovascular diseases |
CN103393708A (en) * | 2013-08-20 | 2013-11-20 | 大理药业股份有限公司 | Ginsenoside-ophiopogonin D composition for treating cardiovascular and cerebrovascular diseases |
CN104623262A (en) * | 2013-11-12 | 2015-05-20 | 雅安三九药业有限公司 | Red ginseng and dwarf lilyturf tuber injection as well as preparation method thereof |
CN104623262B (en) * | 2013-11-12 | 2017-12-19 | 华润三九(雅安)药业有限公司 | A kind of Shenmai injection and preparation method thereof |
CN105004830A (en) * | 2015-07-21 | 2015-10-28 | 成都中医药大学 | HPLC-ELSD method for simultaneously determining five saponin components in ophiopogon japonicus |
CN105004830B (en) * | 2015-07-21 | 2016-06-08 | 成都中医药大学 | Measure the HPLC-ELSD method of 5 kinds of saponin constituents in Radix Ophiopogonis simultaneously |
CN107823420A (en) * | 2017-11-09 | 2018-03-23 | 华润三九(雅安)药业有限公司 | The preparation method and Shenmai injection of Shenmai injection |
CN109709250A (en) * | 2018-12-28 | 2019-05-03 | 南京海昌中药集团有限公司 | The detection method of ginseng antler medical liquor finger-print |
CN112294794A (en) * | 2019-08-01 | 2021-02-02 | 四川大学 | Application of methyl ophiopogonone A in preparation of medicine for preventing and/or treating non-alcoholic fatty liver disease and liver injury |
CN112294794B (en) * | 2019-08-01 | 2021-07-30 | 四川大学 | Application of methyl ophiopogonone A in preparation of medicine for preventing and/or treating non-alcoholic fatty liver disease and liver injury |
Also Published As
Publication number | Publication date |
---|---|
CN101375990B (en) | 2012-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101375990B (en) | Composition for treating cardiovascular disease and preparation thereof | |
CN101401829A (en) | Wild Jinchai liveness extract, preparation and uses thereof | |
CN101972385B (en) | Method for preparing general flavone in star-of-Bethlehem and application thereof to antitumor, anti-inflammatory and analgesic medicines | |
CN101119740A (en) | Use of radix sanguisorbae and its extract for preparing medicament to increase RBC and hemoglobin | |
CN1923241B (en) | Medicine composition containing epimedium extract, uncaria extract, and gastrodine, and its preparation and use | |
CN101224246B (en) | Preparing method of loquat leaf total triterpenic acid and antidiabetic use thereof | |
CN101327237A (en) | Composition containing plant effective component and preparation method and use thereof | |
CN102274260A (en) | Medicinal composition of notoginseng root extract and preparation method thereof | |
Koo et al. | Extraction of hypotensive principles from seeds of Cassia tora | |
CN101623437B (en) | Pulse-activating preparation for injection and preparation method thereof | |
CN100540017C (en) | A kind of Chinese medicine preparation for the treatment of angina pectoris and preparation method thereof | |
CN101190906A (en) | Method for preparing carthamin yellow carthamus B and application thereof | |
CN100563682C (en) | A kind of pharmaceutical composition of making by Folium Crataegi and Radix Rhodiolae and preparation method thereof | |
CN105943681A (en) | Semen litchi steroid saponin extract having function of improving insulin resistance | |
CN101199568A (en) | Medicament compound for treating cardiovascular disease and preparing method thereof | |
CN101468053A (en) | Pharmaceutical composition containing notoginseng and ginseng as well as preparation and application thereof | |
CN107349362B (en) | A pharmaceutical composition for the treatment of diabetic retinopathy | |
CN101745016B (en) | Extraction method of 'ginseng/radix ophiopogonis and schisandra chinensis' and preparation thereof | |
CN104887796A (en) | Anti-altitude-stress rhodiola rosea oral liquid and preparation method thereof | |
CN100333771C (en) | Ginseng and astragalis blood glucose loucring dorpping pill, and its preparing and detecting method | |
CN100484543C (en) | Medicament composition for treating hepatitis, prepartion method and use | |
CN101468060A (en) | Pharmaceutical composition | |
CN115120657B (en) | Traditional Chinese medicine composition and pharmaceutical preparation for impervious capacity expansion in burn shock period and preparation method | |
CN101167784A (en) | Medicinal composition for cardiovascular and cerebrovascular diseases | |
CN101974010B (en) | New compound erigeron breviscapus acid with officinal activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
C41 | Transfer of patent application or patent right or utility model | ||
PB01 | Publication | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20090206 Address after: Unit 502, unit 24, North District, Keyuan residential quarter, Lixia District, Ji'nan, Shandong, China 502 Applicant after: Gong Hong Kong Co-applicant after: Ma Zhenyuan Address before: Building 3, Pioneer Park, No. 26 Huayang Road, Shandong, Ji'nan Applicant before: Jinan Cherish Nature Pharmaceutical Science and Technology Co., Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: GONG HONGGANG Free format text: FORMER OWNER: JINAN TIANRUIBENCAO PHARMACEUTICAL TECHNOLOGY CO., LTD. Effective date: 20090206 |
|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120502 Termination date: 20150829 |
|
EXPY | Termination of patent right or utility model |